•La Jolla NanoMedical (LJNM) is addressing an important unmet need in a $1.78 Billion annual US market

•The technology applies bio-inert nanoparticles and infrared light to eradicate skin cancer tumors

•LJNM management team has successfully led and exited multiple medical companies previously

•LJNM is developing a novel medical device, with a predictable approval pathway

View Artists  →